Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Profex Receives $15.5 Million Venture Capital Investment

This article was originally published in PharmAsia News

Executive Summary

Profex, China's first international dermatology firm, received its first round of venture capital worth $15.5 million from Trident Capital and its China partner Mustang Ventures. The new fund will help it penetration into the fast-growing consumables retail market. Profex differs from other domestic pharmaceutical companies in its business model; by acting as a professional drug agency for the world's top pharmaceutical companies, it has exclusive sales rights for China. The firm has established long-term strategic partnerships with Galderma, GlaxoSmithKline, Roche and Bristol-Meyers Squibb, with full responsibility for products' marketing. Industry insiders said that Profex, with over 30 percent of the local dermatology market share and sales exceeding RMB 1 billion, will list in the U.S. when the timing is right. (Click here for more - Chinese Language)

You may also be interested in...

Impella Safety Update: Data Supports Pump For Qualified Patients

Updated data from a postmarket study of Abiomed’s Impella RP right-heart pump further supports the device’s safety for a specific patient population.

Quality, Safety, MDSAP A Focus For Medtech In New USMCA Trade Agreement

The new US-Mexico-Canada (USMCA) trade agreement includes language on enhancing regulatory compatibility between the three countries by recognizing quality systems audits performed under the Medical Device Single Audit Program (MDSAP). It also stipulates that each trading partner “consider its resources and technical capacity” in ensuring the safety, effectiveness and quality of devices – and more. Medtech industry advocacy group AdvaMed is praising the deal, reached by the three countries on 10 December.

Novo Nordisk Targets Smart Insulin, Stem Cell-Therapies

Novo Nordisk’s CEO talks to Scrip about the promise of glucose-responsive insulin, stem cell therapy, and a diabetes landscape without Sanofi.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts